Latest News

FDA to decide on Spectrum Pharmaceuticals’ neutropenia drug by Oct. 2020



Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen’s Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.

Source link




Related posts

Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma

Newsemia

Global Transplant Diagnostics Market Expected to Grow with a CAGR of 6% Over the Forecast Period, 2019-2025 – ResearchAndMarkets.com

Newsemia

Chronic kidney disease patients face continual, significant gaps in care

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy